Volume 24, Issue 5 (Sep 2022)
Clinicopathological factors associated with pathological upgrading from biopsy to prostatectomy in patients with ISUP grade group ≤2 prostate cancer
Xing Li, Zhi-Xian Wang, Yun-Peng Zhu, Jing Wang, Yi-Sheng Yin, Xiao-Yong Zeng
Asian J Androl 24: 487-493; 10.4103/aja2021108
Abstract |Full Text | PDF

The comparison of survival between active surveillance or watchful waiting and focal laser ablation in patients with low-risk prostate cancer
Jia-Kun Li1, Chi-Chen Zhang1, Shi Qiu1, Kun Jin1, Bo-Yu Cai1, Qi-Ming Yuan1, Xing-Yu Xiong1, Lian-Sha Tang2, Di Jin1, Xiang-Hong Zhou1, Yi-Ge Bao1, Lu Yang1, Qiang Wei1
Asian J Androl 24: 494-499; 10.4103/aja2021113
Abstract |Full Text | PDF

Combined treatment with dihydrotestosterone and lipopolysaccharide modulates prostate homeostasis by upregulating TNF-α from M1 macrophages and promotes proliferation of prostate stromal cells
Yu Tong1, Yi-Jun Guo1, Qin Zhang2, Hai-Xia Bi2, Kai Kai1, Ren-Yuan Zhou1
Asian J Androl 24: 513-520; 10.4103/aja2021114
Abstract |Full Text | PDF

Immunohistochemical analysis of PD-L1 and tumor-infiltrating immune cells expression in the tumor microenvironment of primary signet ring cell carcinoma of the prostate
Qi-Liang Teng1, Xin-Rui Yang2, Shuang Wen3, Zhi-Hong Dai1, Hong-Long Wang3, Tian-Qing Liu3, Liang Wang1, Bo Fan1, Zhi-Yu Liu1
Asian J Androl 24: 525-532; 10.4103/aja202186
Abstract |Full Text | PDF

Mannose inhibits the growth of prostate cancer through a mitochondrial mechanism
Yu-Lin Deng1, Ren Liu1, Zhou-Da Cai2, Zhao-Dong Han3, Yuan-Fa Feng4, Shang-Hua Cai4, Qing-Biao Chen6, Jian-Guo Zhu5, Wei-De Zhong1,3
Asian J Androl 24: 540-548; 10.4103/aja2021104
Abstract |Full Text | PDF

Volume 24, Issue 4 (Jul 2022)
The performance of 18F-PSMA PET/CT in the detection of prostate cancer: a systematic review and meta-analysis
Zhi-Qiang Qin1, Gao-Jian Pan1,2,3, Zheng Xu1, Hao Wang1, Lu-Wei Xu1, Rui-Peng Jia1
Asian J Androl 24: 373-379; 10.4103/aja202162
Abstract |Full Text | PDF

Coexpression of TLR9 and VEGF-C is associated with lymphatic metastasis in prostate cancer
Xian-Zi Zeng1, Zhan-Sen Huang1,2, Hong-Peng Fang1, Jie-Ying Wu1, Qun-Xiong Huang1, Chu-Bin Zhuang1, Jing Zhou3, Jin-Ming Di1
Asian J Androl 24: 380-385; 10.4103/aja202167
Abstract |Full Text | PDF

Prostate Health Index (phi) and its derivatives predict Gleason score upgrading after radical prostatectomy among patients with low-risk prostate cancer
Jia-Qi Yan1, Da Huang1, Jing-Yi Huang1, Xiao-Hao Ruan1, Xiao-Ling Lin2, Zu-Jun Fang2, Yi Gao1, Hao-Wen Jiang2, Yi-Shuo Wu2, Rong Na1, Dan-Feng Xu1
Asian J Androl 24: 406-410; 10.4103/aja202174
Abstract |Full Text | PDF

Volume 24, Issue 3 (May 2022)
The comparison of survival between active surveillance or watchful waiting and focal therapy for low-risk prostate cancer: a real-world study from the SEER database
Qi-Ming Yuan, Tian-Hai Lin, Kun Jin, Shi Qiu, Xiang-Hong Zhou, Di Jin, Jia-Kun Li, Lu Yang, Qiang Wei
Asian J Androl 24: 305-310; 10.4103/aja202159
Abstract |Full Text | PDF PDF

Volume 24, Issue 2 (Mar 2022)
High IL-23+ cells infiltration correlates with worse clinical outcomes and abiraterone effectiveness in patients with prostate cancer
Zheng Liu1,2, Jun-Yu Zhang1,2, Yun-Jie Yang1,2, Kun Chang1,2, Qi-Feng Wang2,3, Yun-Yi Kong2,3, Bo Dai1,2
Asian J Androl 24: 147-153; 10.4103/aja202173
Abstract |Full Text | PDF